Australia: The same but different: Heading off generic market entry which does not patent infringe

Last Updated: 27 February 2015
Article by Katrina Crooks

A preliminary discovery application brought in the Federal Court of Australia by GlaxoSmithKline Australia Pty Ltd (GSK) shortly before Christmas has sparked interest in the potential for patentees to prevent non-patent infringing generic pharmaceutical products entering the Australian market.

Background facts

The paracetamol market in Australia saw significant legal attention in the last months of 2014. In October, following GSK's commencement of proceedings, Apotex Pty Ltd and Generic Partners Pty Ltd gave undertakings to the Court not to supply generic products (which they had admitted an intention to sell) falling within the scope of GSK's sustained released paracetamol patent (the Patent), pending the outcome of infringement and invalidity proceedings in respect of the Patent. GSK has marketed its sustained release products, Panadol Back and Neck Long-Lasting and Panadol Osteo, in Australia since 2000 and Panadol Osteo is the only long-release paracetamol product listed on the PBS, the Australian government subsidy scheme for medicines.

The preliminary discovery application

In November, GSK set its sights on Pharmacor Pty Ltd, which had obtained regulatory approval, and applied for entry on the PBS, for its sustained release OSTEOMOL 665 PARACETAMOL products (the Pharmacor products). GSK applied for preliminary discovery from Pharmacor of various materials, including technical information submitted by it to the Therapeutic Goods Administration (TGA) in support of its approval application. In Australia, a party may be granted preliminary discovery where it reasonably believes that it may have the right to obtain relief from the Court, and requires the materials sought to allow it to decide whether to start Court proceedings.

GSK claimed that it reasonably believed it might be entitled to injunctive relief for breach of provisions of the Australian Consumer Lawprohibiting misleading and deceptive conduct, and required the documentation sought for this purpose.

The Patent claims a pharmaceutical composition comprising a bi-layer tablet having an immediate release phase of paracetamol and a sustained release phase of paracetamol, each layer in certain proportion and the composition having a specified in vitro paracetamol dissolution profile. Correspondence between GSK and Pharmacor indicated that the Pharmacor products did not have the claimed dissolution profile and that the immediate release and sustained release phases were in equal proportion, which did not meet the requirements of the claims. Pharmacor had nevertheless obtained TGA approval for the Pharmacor products as generic products on the basis of bioequivalence with the Panadol products and sought to have the Pharmacor products listed on the PBS as a "new brand" of Panadol Osteo.

GSK claimed that it had reason to believe that the Pharmacor products were not fully therapeutically equivalent to the Panadol products, even though they might meet the TGA bioequivalence requirements. In particular, it pointed to the fact that while the maximum plasma concentration level and bioavailability of the active ingredient might be equivalent in the respective products, in a modified release product, the time taken to reach a therapeutically active plasma concentration level and duration of time over which that concentration level is maintained, are equally important. GSK argued that the differing dissolution rate of the Pharmacor products (a necessary implication of the patent non-infringement position taken by Pharmacor) gave rise to the prospect that these additional features of "therapeutic equivalence" might not be met. On this basis, so the GSK argument went, it would be misleading and deceptive for Pharmacor to market the products as bioequivalent to the Panadol products.

The outcome

Pharmacor had indicated to the Court that the only relevant statements it would make to pharmacists and consumers in marketing its product were to the effect that the TGA had approved the products as being bioequivalent with the Panadol products, and that they had been approved on the PBS as interchangeable with the Panadol Osteo product. It indicated that it would not refer in general terms to bioequivalence or interchangeability of the respective products. Notwithstanding this self-imposed limitation, Justice Beach found that GSK had a potential claim against Pharmacor. While such statements were literally true, they could potentially mislead by constituting a half-truth or omission as to other possible therapeutic differences between the products.

It was firstly clear that there were differences between the Pharmacor products and the Panadol products. Caught on one side by the prospect of patent infringement, Pharmacor was forced to accept that the dissolution profile of its products did not match that specified in the Patent; on the other hand it was not contested that the Panadol products were within its scope. This constituted a meaningful difference between the respective products. Justice Beach did not consider the conclusion of the TGA that the products were bioequivalent to preclude this finding. The concept of bioequivalence as used by the TGA had a "degree of imprecision and variability", on one view aligned with the overriding safety and efficacy imperatives governing its activities. The very fact that the products had differing dissolution profiles, yet were found bioequivalent by the TGA, illustrated this point. While not reaching a conclusion on the point (this was indeed the very purpose of obtaining the preliminary discovery), Justice Beach determined that GSK had a reasonable belief that Panadol Osteo had different therapeutic effects to the Pharmacor Products.

Although Justice Beach found that Pharmacor had not engaged in any misleading conduct in its dealings with the TGA and in relation to entry on the PBS, he concluded that end consumers could take the statement "approved by the TGA as bioequivalent to Panadol Osteo" to mean that the Pharmacor products delivered all the same benefits as Panadol Osteo. Pharmacists could also gloss over relevant distinctions and were likely to treat the products, for all relevant purposes, as the same as the Panadol Osteo products. As a result, Pharmacor could not "hide behind" the TGA's labels or ascriptions. A potential claim for misleading conduct in breach of the Australian Consumer Law was made out, and preliminary discovery granted on that basis.


Pharmacor was required to provide the relevant material to GSK by 14 November 2014. From 1 December 2014 the Pharmacor products were listed on the PBS, GSK having taken no injunctive action in the meantime, despite presumably receiving the relevant material from Pharmacor under the preliminary discovery application. This was significant not only for Pharmacor's market entry, but also to GSK's positionvis a vis the other generic companies who had given undertakings to the Court not to market their generic products. Following the launch of Pharmacor's products, Apotex and Generic Partners applied to the Court to be discharged from their undertakings not to market, on the basis of the change of circumstances brought about by Pharmacor's market entry. These applications were ultimately not successful, however given the potential implications (foreshadowed in the original preliminary discovery application), one expects that the material discovered by Pharmacor may not have been sufficient to support the existence of therapeutic differences, so as to give basis for injunctive relief.

Nevertheless, as we see more and more formulation patents, which allow greater possibilities for generic companies to market products containing the same active ingredient without infringing a relevant patent, the prospects for this kind of case appear greater. There may also be opportunities for innovators to seek to prevent generic companies promoting products as generic equivalents after patent expiry (even of an API patent) in any case where the formulation of the generic product is different to that of the original patented product, if a therapeutic difference can be established to flow from the different formulation.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Shelston IP has been awarded the MIP Global Award for Australian IP Firm of the Year 2013.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Katrina Crooks
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions